Effect of long-term cabergoline therapy on the immunological pattern and pituitary function of patients with idiopathic hyperprolactinaemia positive for antipituitary antibodies

Clinical Endocrinology

Volumn 69, Issue 2, 2008, Pages 285-291

  De Bellis, A ^a   Colao, A ^b   Savoia, A ^a   Coronella, C ^a   Pasquali, D ^a   Conte, M ^a   Pivonello, R ^b   Bellastella, A ^a   Sinisi, A A ^a   Bizzarro, A ^a   Lombardi, G ^b   Bellastella, G ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CABERGOLINE; PITUITARY ANTIBODY; PROLACTIN;

ADULT; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CONVALESCENCE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS FUNCTION; HYPOPHYSITIS; IDIOPATHIC DISEASE; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; LOADING DRUG DOSE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AUTOANTIBODIES; AUTOIMMUNE DISEASES; COHORT STUDIES; DOPAMINE AGONISTS; ERGOLINES; FEMALE; HORMONE ANTAGONISTS; HUMANS; HYPERPROLACTINEMIA; LONGITUDINAL STUDIES; MALE; PITUITARY DISEASES; PITUITARY FUNCTION TESTS; PITUITARY GLAND; SEROEPIDEMIOLOGIC STUDIES; THYROID HORMONES; THYROTROPIN; TIME FACTORS;

EID: 47549085037     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03200.x     Document Type: Article

References (45)

1. Ben-Jonathan, N., Mershon, J.L., Allen, D.L. Steinmetz, R.W. (1996) Extra-pituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocrine Reviews, 17, 639 669.
2. Vera-Lastra, O., Jara, L.J. Espinoza, L.R. (2002) Prolactin and autoimmunity. Autoimmunity Reviews, 1, 360 364.
3. Bazan, J.F. (1989) A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor β-chain. Biochemistry and Biophysics Research Communications, 164, 788 797.
4. Bole-Feysot, C., Goffin, V., Edery, M., Binart, N. Kelly, P.A. (1998) Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocrine Reviews, 19, 225 268.
5. Matera, L. (1997) Action of pituitary and lymphocyte prolactin. Neuroimmunomodulation, 4, 171 180.
6. Montgomery, D.W. (2001) Prolactin production by immune cells. Lupus, 10, 665 675.
7. Jacobi, A.M., Rohde, W., Ventz, M., Riemekasten, G., Burmester, G.R. Hiepe, F. (2001) Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Lupus, 10, 554 561.
8. Chikanza, I.C., Petrou, P., Chrousos, G., Kingsley, G. Panayi, G.S 1993) Excessive and dysregulated secretion of prolactin in rheumatoid arthritis: immunopathogenetic and therapeutic implications. British Journal of Rheumatology, 32, 445 448.
9. Azar, S.T. Yamout, B. (1999) Prolactin secretion is increased in patients with multiple sclerosis. Endocrine Research, 25, 207 214.
10. De Bellis, A., Bizzarro, A., Pivonello, R., Lombardi, G. Bellastella, A. (2005) Prolactin and autoimmunity. Pituitary, 8, 25 30.
11. Walker, S.E., Allen, S.H., Hoffman, R.W. McMurray, R.W. (1995) Prolactin: a stimulator of disease activity in systemic lupus erythematosus. Lupus, 4, 3 9.
12. Neidhart, M. (1998) Prolactin in autoimmune diseases. Proceedings of the Society of Experimental Biology and Medicine, 217, 408 419.
13. Lever, E.G. McKerron, C.G. (1984) Autoimmune Addison's disease associated with hyperprolactinemia. Clinical Endocrinology, 21, 451 457.
14. Kapur, G., Patwari, A.K., Narayan, S. Anand, V.K. (2004) Serum prolactin in celiac disease. Journal of Tropical Pediatrics, 50, 37 40.
15. Cheung, C.C., Ezzat, S., Smyth, H.S. Asa, S.L. (2001) The spectrum and significance of primary hypophysitis. Journal of Clinical Endocrinology and Metabolism, 86, 1048 1053.
16. Ezzat, S. Josse, R.G. (1997) Autoimmune hypophysitis. Trends in Endocrinology and Metabolism, 8, 74 80.
17. Bellastella, A., Bizzarro, A., Coronella, C., Bellastella, G., Sinisi, A.A. De Bellis, A. (2003) Lymphocytic hypophysitis: a rare or underestimated disease? European Journal of Endocrinology, 149, 363 376.
18. Caturegli, P., Newschaffer, C., Olivi, A., Pomper, M.G., Burger, P.C. Rose, N.R. (2005) Autoimmune hypophysitis. Endocrine Reviews, 26, 599 614.
19. Mauerhoff, T., Mirakian, R. Bottazzo, G.F. (1987) Autoimmunity and the pituitary. In : D. Doniach, G.F. Bottazzo ed. Bailliere's Clinics in Immunology and Allergy. WB Saunders Company, London, Chapter 11 : 217 235.
20. De Bellis, A., Bizzarro, A. Bellastella, A. (2005) Pituitary antibodies and lymphocytic hypophysitis. Best Practice and Research Clinical Endocrinology and Metabolism, 19, 67 84.
21. Manetti, L., Lupi, I., Morselli, L.L., Albertini, S., Cosottini, M., Grasso, L., Genovesi, M., Pinna, G., Mariotti, S., Bogazzi, F., Bartalena, L. Martino, E. (2007) Prevalence and functional significance of antipituitary antibodies in patients with autoimmune and non-autoimmune thyroid diseases. Journal of Clinical Endocrinology and Metabolism, 92, 2176 2181.
22. McMurray, R.W. (2001) Bromocriptine in reumathic and autoimmune diseases. Arthritis and Rheumatism, 31, 21 32.
23. Alvarez-Nemegyei, J., Cobarrubias-Cobos, A., Escalante-Triay, F., Sosa-Munoz, J., Miranda, J.M. Jara, L.J. (1998) Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study. Lupus, 7, 414 419.
24. Colao, A., Di Sarno, A., Cappabianca, P., Di Somma, C., Pivonello, R. Lombardi, G. (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. New England Journal of Medicine, 349, 2023 2033.
25. Casanueva, F.F., Molitch, M.E., Schlechte, J.A., Abs, R., Bonert, V., Bronstein, M.D., Brue, T., Cappabianca, P., Colao, A., Fahlbusch, R., Fideleff, H., Hadani, M., Kelly, P., Kleinberg, D., Laws, E., Marek, J., Scanlon, M., Sobrinho, L.G., Wass, J.A. Giustina, A. (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clinical Endocrinology, 65, 265 273.
26. Slørdal, L. Spigset, O. (2006) Heart failure induced by non-cardiac drugs. Drug Safety, 29, 567 586.
27. Martin, M., Iglesias-Cubero, G., Diaz Molina, B. Moris De la Tassa, C. (2007) Mitral heart disease due to cabergoline. International Journal of Cardiology, 2, 7 8.
28. Schade, R., Andersohn, F., Suissa, S., Haverkamp, W. Garbe, E. (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. New England Journal of Medicine, 4, 29 38.
29. Roth, B.L. (2007) Drugs and valvular heart disease. New England Journal of Medicine, 4, 6 9.
30. De Bellis, A., Bizzarro, A., Conte, M., Perrino, S., Coronella, C., Solimeno, S., Sinisi, A.M., Stile, L.A., Pisano, G. Bellastella, A. (2003) Antipituitary antibodies in adults with apparently idiopathic growth hormone deficiency and in adults with autoimmune endocrine diseases. Journal of Clinical Endocrinology and Metabolism, 88, 650 654.
31. De Bellis, A., Sinisi, A.A., Conte, M., Coronella, C., Bellastella, G., Esposito, D., Pasquali, D., Ruocco, G., Bizzarro, A. Bellastella, A. (2007) Antipituitary antibodies against gonadotropin-secreting cells in adult male patients with apparently idiopathic hypogonadotropic hypogonadism. Journal of Clinical Endocrinology and Metabolism, 92, 604 607.
32. Suliman, A.M., Smith, T.P., Gibney, J. McKenna, T.J. (2003) Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: application of a new strict laboratory definition of macroprolactinemia. Clinical Chemistry, 49, 1504 1509.
33. Ghigo, E., Aimaretti, G., Arvat, E. Camanni, F. (2001) Growth hormone releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults. Endocrine, 15, 29 38.
34. Paul, M. (2003) Stewart The adrenal cortex. In : P.R. Larsen, H.M. Kronenberg, S. Melmed, K.S. Polonsky eds. Williams Textbook of Endocrinology, 10th edn. Saunders, Philadelphia, 491 551.
35. Kramer, C.K., Tourinho, T.F., de Castro, W.P. da Costa Oliveira, M. (2005) Association between systemic lupus erythematosus, rheumatoid arthritis, hyperprolactinemia and thyroid autoantibodies. Archives of Medical Research, 36, 54 58.
36. Tashiro, T., Sano, T., Xu, B., Wakatsuki, S., Kagawa, N., Nishioka, H., Yamada, S. Kovacs, K. (2002) Spectrum of different types of hypophysitis: a clinicopathologic study of hypophysitis in 31 cases. Endocrine Pathology, 13, 183 195.
37. De Bellis, A., Colao, A., Di Salle, F., Muccitelli, V.I., Iorio, S., Perrino, S., Pivonello, R., Coronella, C., Bizzarro, A., Lombardi, G. Bellastella, A. (1999) A longitudinal study of vasopressin cell antibodies, posterior pituitary function, and magnetic resonance imaging evaluations in subclinical autoimmune central diabetes insipidus. Journal of Clinical Endocrinology and Metabolism, 84, 3047 3051.
38. De Bellis, A., Bizzarro, A., Rossi, R., Paglionico, V.A., Criscuolo, T., Lombardi, G. Bellastella, A. (1993) Remission of subclinical adrenocortical failure in subjects with adrenal autoantibodies. Journal of Clinical Endocrinology and Metabolism, 76, 1002 1007.
39. Laureti, S., De Bellis, A., Muccitelli, V.I., Calcinaro, F., Bizzarro, A., Rossi, R., Bellastella, A., Santeusanio, F. Falorni, A. (1998) A Levels of adrenocortical autoantibodies correlate with the degree of adrenal dysfunction in subjects with preclinical Addison's disease. Journal of Clinical Endocrinology and Metabolism, 83, 3507 3511.
40. De Bellis, A., Salerno, M., Conte, M., Coronella, C., Tirelli, G., Battaglia, M., Esposito, V., Ruocco, G., Bellastella, G., Bizzarro, A. Bellastella, A. (2006) Antipituitary antibodies recognizing growth hormone (GH)-producing cells in children with idiopathic GH deficiency and in children with idiopathic short stature. Journal of Clinical Endocrinology and Metabolism, 91, 2484 2489.
41. Serri, O., Li, L., Mamputu, J.C., Beauchamp, M.C., Maingrette, F. Renier, G. (2006) The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clinical Endocrinology, 64, 366 370.
42. Gomez, R., Simon, C., Remohi, J. Pellicer, A. (2002) Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology, 143, 4339 4348.
43. Gomez, R., Gonzalez-Izquierdo, M., Zimmermann, R.C., Novella-Maestre, E., Alonso-Muriel, I., Sanchez-Criado, J., Remohi, J. Simon, C. (2006) Pellicer. A Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology, 147, 5400 5411.
44. Cristina, C., Díaz-Torga, G., Baldi, A., Góngora, A., Rubinstein, M., Low, M.J. Becú-Villalobos, D. (2005) Increased pituitary vascular endothelial growth factor-α in dopaminergic D2 receptor knockout female mice. Endocrinology, 146, 2952 2962.
45. Partanen, T.A., Arola, J., Saaristo, A., Jussila, L., Ora, A., Miettinen, M., Stacker, S.A., Achen, M.G. Alitalo, K. (2000) VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB Journal, 14, 2087 2096.